Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph

Efstathios Karathanasis, Sankararaman Suryanarayanan, Sri R. Balusu, Kathleen McNeeley, Ioannis Sechopoulos, Andrew Karellas, Ananth V. Annapragada, Ravi V. Bellamkonda

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: To prospectively predict the effectiveness of a clinically used nanochemotherapeutic agent by detecting and measuring the intratumoral uptake of an x-ray contrast agent nanoprobe by using digital mammography. Materials and Methods All animal procedures were approved by the institutional : animal care and use committee. A long-circulating 100 nm-scale injectable liposomal probe encapsulating 155 mg/mL iodine was developed. Preliminary studies were performed to identify the agent dose that would result in adequate tumor enhancement without enhancement ofthe normal vasculature in rats. This dose was used to image a rat breast tumor (n = 14) intermittently for 3 days by using a digital mammography system; subsequently, the animals were treated with liposomal doxorubicin. The predictive capability of the probe was characterized by creating good- and bad-prognosis subgroups, on the basis of tumor enhancement found during imaging, and analyzing the tumor growth after treatment of the animals in these two subgroups. Results: A dose of 455 mg of iodine per kilogram of body weight was found to produce an undetectable signal from the blood while achieving enough intratumoral accumulation of the probe to produce adequate signal for detection. The good- and bad-prognosis subgroups demonstrated differential tumor growth rates (P <.003). An inverse linear relationship between the contrast enhancement rate constant during imaging and the tumor growth rate constant during treatment was found (slope = -0.576, R 2 = 0.838). Conclusion: In this animal model, quantitative measurement of vascular permeability enabled prediction of therapeutic responsiveness of tumors to liposomal doxorubicin.

Original languageEnglish (US)
Pages (from-to)398-406
Number of pages9
JournalRadiology
Volume250
Issue number2
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Nanoparticles
Drug Therapy
Neoplasms
Mammography
Iodine
Growth
Animal Care Committees
Capillary Permeability
Contrast Media
Therapeutics
Animal Models
Body Weight
X-Rays
Breast Neoplasms
Injections
liposomal doxorubicin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Karathanasis, E., Suryanarayanan, S., Balusu, S. R., McNeeley, K., Sechopoulos, I., Karellas, A., ... Bellamkonda, R. V. (2009). Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph. Radiology, 250(2), 398-406. https://doi.org/10.1148/radiol.2502080801

Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph. / Karathanasis, Efstathios; Suryanarayanan, Sankararaman; Balusu, Sri R.; McNeeley, Kathleen; Sechopoulos, Ioannis; Karellas, Andrew; Annapragada, Ananth V.; Bellamkonda, Ravi V.

In: Radiology, Vol. 250, No. 2, 01.02.2009, p. 398-406.

Research output: Contribution to journalArticle

Karathanasis, E, Suryanarayanan, S, Balusu, SR, McNeeley, K, Sechopoulos, I, Karellas, A, Annapragada, AV & Bellamkonda, RV 2009, 'Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph', Radiology, vol. 250, no. 2, pp. 398-406. https://doi.org/10.1148/radiol.2502080801
Karathanasis E, Suryanarayanan S, Balusu SR, McNeeley K, Sechopoulos I, Karellas A et al. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph. Radiology. 2009 Feb 1;250(2):398-406. https://doi.org/10.1148/radiol.2502080801
Karathanasis, Efstathios ; Suryanarayanan, Sankararaman ; Balusu, Sri R. ; McNeeley, Kathleen ; Sechopoulos, Ioannis ; Karellas, Andrew ; Annapragada, Ananth V. ; Bellamkonda, Ravi V. / Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph. In: Radiology. 2009 ; Vol. 250, No. 2. pp. 398-406.
@article{710129e2598d46f69fbd6f04521b0534,
title = "Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph",
abstract = "Purpose: To prospectively predict the effectiveness of a clinically used nanochemotherapeutic agent by detecting and measuring the intratumoral uptake of an x-ray contrast agent nanoprobe by using digital mammography. Materials and Methods All animal procedures were approved by the institutional : animal care and use committee. A long-circulating 100 nm-scale injectable liposomal probe encapsulating 155 mg/mL iodine was developed. Preliminary studies were performed to identify the agent dose that would result in adequate tumor enhancement without enhancement ofthe normal vasculature in rats. This dose was used to image a rat breast tumor (n = 14) intermittently for 3 days by using a digital mammography system; subsequently, the animals were treated with liposomal doxorubicin. The predictive capability of the probe was characterized by creating good- and bad-prognosis subgroups, on the basis of tumor enhancement found during imaging, and analyzing the tumor growth after treatment of the animals in these two subgroups. Results: A dose of 455 mg of iodine per kilogram of body weight was found to produce an undetectable signal from the blood while achieving enough intratumoral accumulation of the probe to produce adequate signal for detection. The good- and bad-prognosis subgroups demonstrated differential tumor growth rates (P <.003). An inverse linear relationship between the contrast enhancement rate constant during imaging and the tumor growth rate constant during treatment was found (slope = -0.576, R 2 = 0.838). Conclusion: In this animal model, quantitative measurement of vascular permeability enabled prediction of therapeutic responsiveness of tumors to liposomal doxorubicin.",
author = "Efstathios Karathanasis and Sankararaman Suryanarayanan and Balusu, {Sri R.} and Kathleen McNeeley and Ioannis Sechopoulos and Andrew Karellas and Annapragada, {Ananth V.} and Bellamkonda, {Ravi V.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1148/radiol.2502080801",
language = "English (US)",
volume = "250",
pages = "398--406",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph

AU - Karathanasis, Efstathios

AU - Suryanarayanan, Sankararaman

AU - Balusu, Sri R.

AU - McNeeley, Kathleen

AU - Sechopoulos, Ioannis

AU - Karellas, Andrew

AU - Annapragada, Ananth V.

AU - Bellamkonda, Ravi V.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Purpose: To prospectively predict the effectiveness of a clinically used nanochemotherapeutic agent by detecting and measuring the intratumoral uptake of an x-ray contrast agent nanoprobe by using digital mammography. Materials and Methods All animal procedures were approved by the institutional : animal care and use committee. A long-circulating 100 nm-scale injectable liposomal probe encapsulating 155 mg/mL iodine was developed. Preliminary studies were performed to identify the agent dose that would result in adequate tumor enhancement without enhancement ofthe normal vasculature in rats. This dose was used to image a rat breast tumor (n = 14) intermittently for 3 days by using a digital mammography system; subsequently, the animals were treated with liposomal doxorubicin. The predictive capability of the probe was characterized by creating good- and bad-prognosis subgroups, on the basis of tumor enhancement found during imaging, and analyzing the tumor growth after treatment of the animals in these two subgroups. Results: A dose of 455 mg of iodine per kilogram of body weight was found to produce an undetectable signal from the blood while achieving enough intratumoral accumulation of the probe to produce adequate signal for detection. The good- and bad-prognosis subgroups demonstrated differential tumor growth rates (P <.003). An inverse linear relationship between the contrast enhancement rate constant during imaging and the tumor growth rate constant during treatment was found (slope = -0.576, R 2 = 0.838). Conclusion: In this animal model, quantitative measurement of vascular permeability enabled prediction of therapeutic responsiveness of tumors to liposomal doxorubicin.

AB - Purpose: To prospectively predict the effectiveness of a clinically used nanochemotherapeutic agent by detecting and measuring the intratumoral uptake of an x-ray contrast agent nanoprobe by using digital mammography. Materials and Methods All animal procedures were approved by the institutional : animal care and use committee. A long-circulating 100 nm-scale injectable liposomal probe encapsulating 155 mg/mL iodine was developed. Preliminary studies were performed to identify the agent dose that would result in adequate tumor enhancement without enhancement ofthe normal vasculature in rats. This dose was used to image a rat breast tumor (n = 14) intermittently for 3 days by using a digital mammography system; subsequently, the animals were treated with liposomal doxorubicin. The predictive capability of the probe was characterized by creating good- and bad-prognosis subgroups, on the basis of tumor enhancement found during imaging, and analyzing the tumor growth after treatment of the animals in these two subgroups. Results: A dose of 455 mg of iodine per kilogram of body weight was found to produce an undetectable signal from the blood while achieving enough intratumoral accumulation of the probe to produce adequate signal for detection. The good- and bad-prognosis subgroups demonstrated differential tumor growth rates (P <.003). An inverse linear relationship between the contrast enhancement rate constant during imaging and the tumor growth rate constant during treatment was found (slope = -0.576, R 2 = 0.838). Conclusion: In this animal model, quantitative measurement of vascular permeability enabled prediction of therapeutic responsiveness of tumors to liposomal doxorubicin.

UR - http://www.scopus.com/inward/record.url?scp=61749095523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749095523&partnerID=8YFLogxK

U2 - 10.1148/radiol.2502080801

DO - 10.1148/radiol.2502080801

M3 - Article

C2 - 19188313

AN - SCOPUS:61749095523

VL - 250

SP - 398

EP - 406

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -